-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Contrasting Ontrak (NASDAQ:OTRK) & Lisata Therapeutics (NASDAQ:LSTA)
Contrasting Ontrak (NASDAQ:OTRK) & Lisata Therapeutics (NASDAQ:LSTA)
Ontrak (NASDAQ:OTRK – Get Rating) and Lisata Therapeutics (NASDAQ:LSTA – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.
Earnings and Valuation
This table compares Ontrak and Lisata Therapeutics' revenue, earnings per share and valuation.
Get Ontrak alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ontrak | $84.13 million | 0.26 | -$37.14 million | ($3.38) | -0.25 |
| Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.30 |
Lisata Therapeutics has lower revenue, but higher earnings than Ontrak. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Ontrak, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
49.8% of Ontrak shares are held by institutional investors. Comparatively, 6.0% of Lisata Therapeutics shares are held by institutional investors. 46.6% of Ontrak shares are held by insiders. Comparatively, 2.2% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.Profitability
This table compares Ontrak and Lisata Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ontrak | -279.90% | -183.58% | -92.71% |
| Lisata Therapeutics | N/A | -29.53% | -27.96% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Ontrak and Lisata Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ontrak | 0 | 0 | 0 | 0 | N/A |
| Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Ontrak presently has a consensus price target of $2.27, suggesting a potential upside of 171.46%. Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 312.09%. Given Lisata Therapeutics' higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Ontrak.
Volatility and Risk
Ontrak has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.
About Ontrak
(Get Rating)
Ontrak, Inc. engages in the provision of data analytics based behavioral health management and integrated treatment services to health plans. It offers services through its Ontrak platform solution, which is designed to improve member health, and at the same time, lower costs to the insurer for underserved populations where behavioral health conditions cause or exacerbate co-existing medical conditions. The company was founded by Terren S. Peizer in February 2003 and is headquartered in Santa Monica, CA.
About Lisata Therapeutics
(Get Rating)
Lisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.
Receive News & Ratings for Ontrak Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ontrak and related companies with MarketBeat.com's FREE daily email newsletter.
Ontrak (NASDAQ:OTRK – Get Rating) and Lisata Therapeutics (NASDAQ:LSTA – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.
Ontrak (NASDAQ: OTRK — 獲得評分) 和利莎塔治療 (NASDAQ: LSTA — 獲得評分) 都是小型公司, 但哪個是優越的業務?我們將根據兩家企業的風險，股息，盈利能力，收益，分析師建議，估值和機構所有權的強度進行對比。
Earnings and Valuation
收益及估值
This table compares Ontrak and Lisata Therapeutics' revenue, earnings per share and valuation.
此表比較安特拉克和利薩塔治療的收入，每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ontrak | $84.13 million | 0.26 | -$37.14 million | ($3.38) | -0.25 |
| Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.30 |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股盈利 | 市盈比率 | |
| 昂特拉克 | 八千四百一十三萬美元 | 0.26 | -37.5 億美元 | (三百三十八元) | -0.25 |
| 利莎塔治療 | N/A | N/A | -27.47 百萬美元 | (十二二三元) | -0.30 |
Lisata Therapeutics has lower revenue, but higher earnings than Ontrak. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Ontrak, indicating that it is currently the more affordable of the two stocks.
利莎塔治療學的收入較低，但收入高於 Ontrak。Lisata 治療以比 Ontrak 更低的價格與收益比進行交易，這表明它目前在兩隻股票中價格更便宜。
Insider & Institutional Ownership
內幕和機構所有權
Profitability
盈利
This table compares Ontrak and Lisata Therapeutics' net margins, return on equity and return on assets.
此表格比較了安特拉克和利薩塔治療的淨利潤率，股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Ontrak | -279.90% | -183.58% | -92.71% |
| Lisata Therapeutics | N/A | -29.53% | -27.96% |
| 淨利潤 | 權益回報率 | 資產回報率 | |
| 昂特拉克 | -279.90% | -183.58% | -92.71% |
| 利莎塔治療 | N/A | -29.53% | -27.96% |
Analyst Ratings
分析師評級
This is a breakdown of current ratings and recommmendations for Ontrak and Lisata Therapeutics, as provided by MarketBeat.
這是由 MarketBeat 提供的安特拉克和利莎塔治療學的當前評級和推薦的細分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ontrak | 0 | 0 | 0 | 0 | N/A |
| Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| 銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
| 昂特拉克 | 0 | 0 | 0 | 0 | N/A |
| 利莎塔治療 | 0 | 0 | 2 | 0 | 3.00 |
Ontrak presently has a consensus price target of $2.27, suggesting a potential upside of 171.46%. Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 312.09%. Given Lisata Therapeutics' higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Ontrak.
安特拉克目前的一致價格目標為 2.27 美元，表明潛在的上行空間為 171.46％。利莎塔治療學的共識價格目標為 15.00 美元，表明潛在的上行空間為 312.09％。鑑於 Lisata 治療的可能較高的上行空間，分析師清楚地認為 Lisata 治療比 Ontrak 更有利。
Volatility and Risk
波動性和風險
Ontrak has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.
安特拉克的測試版為 2.16，表明其股價比標普 500 的波動性高 116％。相比之下，利莎塔治療的測試版為 1.04，表明其股價比標普 500 高出 4％ 的波動性。
About Ontrak
關於安達
(Get Rating)
(取得評分)
Ontrak, Inc. engages in the provision of data analytics based behavioral health management and integrated treatment services to health plans. It offers services through its Ontrak platform solution, which is designed to improve member health, and at the same time, lower costs to the insurer for underserved populations where behavioral health conditions cause or exacerbate co-existing medical conditions. The company was founded by Terren S. Peizer in February 2003 and is headquartered in Santa Monica, CA.
Ontrak, Inc. 致力於為健康計劃提供基於數據分析的行為健康管理和綜合治療服務。它通過其 Ontrak 平台解決方案提供服務，該解決方案旨在改善會員健康狀況，同時為行為健康狀況導致或加劇共存的醫療條件而降低服務不足的人群的成本。該公司由泰倫 ·S· 佩澤於 2003 年 2 月成立，總部位於加利福尼亞州聖莫尼卡。
About Lisata Therapeutics
關於利莎塔治療
(Get Rating)
(取得評分)
Lisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.
利莎塔治療, 公司. 開發生物製藥.它致力於治療晚期實體瘤和其他重大疾病的創新療法的發現，開發和商業化。它旨在通過激活一種新穎的吸收途徑來改變腫瘤微環境，從而使抗癌藥物更有效地穿透實體腫瘤。該公司總部位於新澤西州姥嶺。
Receive News & Ratings for Ontrak Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ontrak and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Ontrak 日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Ontrak 及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧